Adherium

Adherium Equity Turnover

The Equity Turnover of Adherium (ADR.AX) as of Oct 28, 2026 is -1.63. In the previous year, Equity Turnover was -0.17 — a change of 848.99% (lower).

Equity Turnover

-1.63

YoY

848.99%

Last updated:

Equity Turnover of Adherium is 2026 -1.63 . Equity Turnover of Adherium was 2025 -0.17 . It decreases by 848.99% lower compared to the previous year.

The Adherium Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2019
3.35 AUD
Jan 1, 2020
0.66 AUD
Jan 1, 2021
0.03 AUD
Jan 1, 2022
0.10 AUD
Jan 1, 2023
0.35 AUD
Jan 1, 2024
0.13 AUD
Jan 1, 2025
-0.17 AUD
Jan 1, 2026
-1.63 AUD
The Adherium Equity Turnover history
YEAREquity TurnoverYoY
-1.63+848.99%
-0.17-232.21%
0.13-62.57%
0.35+262.95%
0.10+234.39%
0.03-95.64%
0.66-80.42%
3.35+631.04%
0.46+343.07%
0.10+35.10%
0.08-9.12%
0.08-62.10%
0.22—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adherium Stock analysis

What does Adherium do? Adherium Ltd develops and supplies connected medical devices and respiratory medications for patients, pharmaceutical companies, healthcare providers, and contract research organizations. The company generates revenue through its Hailie sensor technology and cloud-based data platform, which provides real-time feedback on patients' use of inhaled medication. The Hailie Remote Patient Management (RPM) Solution, Hailie Sensors, and Hailie Solution are key products sold to healthcare providers, payers, and pharmaceutical companies. These solutions enable optimal management of severe asthma and COPD, reduce healthcare costs, and offer remote monitoring capabilities for patients and physicians. The Hailie Sensor technology wraps around inhalers and connects via Bluetooth to capture medication use data, which is transmitted to the cloud-based Hailie platform. This platform delivers real-time feedback to patients through the Hailie app and to physicians via the Hailie portal. The company's focus on patient medication adherence and remote monitoring drives demand from healthcare providers seeking to improve treatment outcomes and from pharmaceutical companies aiming to enhance patient engagement with their respiratory medications. Adherium's products target segments including patients with severe asthma and COPD, healthcare providers managing chronic conditions, payers interested in cost reduction, and pharmaceutical companies developing respiratory medications. The company's revenue model centers on selling its sensor technology, cloud platform access, and integrated RPM solutions to these key segments, leveraging FDA-cleared devices to ensure compliance and reliability in healthcare settings. Adherium is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adherium stock

Equity Turnover of Adherium is -1.63 in 2026.

Equity Turnover of Adherium changed from -0.17 to -1.63, representing a 848.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover Adherium since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Adherium with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Adherium

All Key Metrics — Adherium